Reengineering Penicillin to Combat MRSA to resemble Ceftaroline through Chemical Synthesis

MRSA (Methicillin-Resistant Staphylococcus aureus) is a strain of bacteria resistant to many common antibiotics, such as methicillin and penicillin. It is a common cause of severe infections, including pneumonia and sepsis. Antibiotics like Ceftaroline have shown significant efficacy against MRSA. However, their high costs and limited accessibility make them less viable for underserved populations. In contrast, while widely available and cost-effective, penicillin remains ineffective against MRSA due to many bacteria evolving resistance mechanisms. This disparity underscores the urgent need for a solution that upholds clinical effectiveness and is economically accessible, especially in resource-limited environments like underfunded communities. Our study focuses on bridging the issue of antibiotic resistance by reengineering penicillin to combat MRSA. Through chemical synthesis, we aim to modify the R1-side chain of penicillin to resemble ceftaroline, a potent but pricey drug proven to be effective against the MRSA bacterium. By leveraging this structural modification, we strive to produce an effective compound against MRSA that is accessible to populations worldwide due to lower costs. As antibiotic resistance poses substantial challenges, this research could pave the way for a more equitable and efficient approach to combating MRSA infections.